Episode
J&J Walks Away from Obesity Drug Rush
- Published
- Jun 24, 2026
- Duration seconds
- 154
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/raleigh-news-today-2-min-news-the-daily-news-now-7564076/episodes/j-j-walks-away-from-obesity-drug-rush/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/raleigh-news-today-2-min-news-the-daily-news-now-7564076/j-j-walks-away-from-obesity-drug-rush.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Johnson & Johnson is boldly skipping the booming obesity drug race, opting instead to double down on cancer and brain disease research — a strategic pivot aimed at becoming the world’s top cancer drug company by 2030. CEO Joaquin Duato’s decision, backed by $3 billion in acquisitions, reflects a calculated move to avoid a crowded market dominated by rivals like Eli Lilly and Novo Nordisk. With blockbuster drugs losing steam and the obesity market projected to hit $95 billion, J&J sees oncology as a more defensible, high-impact growth path — one that could deliver $50 billion in sales by 2030. The gamble hinges on maintaining Darzalex’s momentum and successfully launching new therapies, but early signs are promising, with stock gains reflecting investor confidence. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/96f672602f4ff26a